Analyst Price Targets — KURA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:32 am | — | Lake Street | $23.00 | $8.72 | TheFly | Kura Oncology initiated with a Buy at Lake Street |
| March 13, 2026 1:10 pm | David Dai | UBS | $15.00 | $8.60 | StreetInsider | Kura Oncology (KURA) PT Lowered to $15 at UBS |
| January 13, 2026 2:14 pm | — | Leerink Partners | $20.00 | $9.03 | TheFly | Kura Oncology price target lowered to $20 from $25 at Leerink |
| November 24, 2025 11:29 am | Etzer Darout | Barclays | $28.00 | $11.17 | TheFly | Kura Oncology price target raised to $28 from $11 at Barclays |
| November 14, 2025 1:01 pm | — | Wedbush | $38.00 | $11.57 | TheFly | Kura Oncology price target raised to $38 from $36 at Wedbush |
| November 14, 2025 11:53 am | Joseph Pantginis | H.C. Wainwright | $40.00 | $11.78 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA) |
| March 6, 2025 12:21 pm | — | UBS | $14.00 | $7.70 | TheFly | Kura Oncology price target lowered to $14 from $27 at UBS |
| November 22, 2024 6:33 pm | Bradley Canino | Stifel Nicolaus | $11.00 | $10.80 | StreetInsider | Kura Oncology (KURA) PT Lowered to $11 at Stifel |
| October 24, 2024 4:03 am | David Dai | UBS | $27.00 | $17.02 | StreetInsider | UBS Starts Kura Oncology (KURA) at Buy |
| October 14, 2024 12:36 am | Bradley Canino | Stifel Nicolaus | $19.00 | $18.58 | StreetInsider | Stifel Downgrades Kura Oncology (KURA) to Hold |
Latest News for KURA
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy
SG Americas Securities LLC grew its stake in Kura Oncology, Inc. (NASDAQ: KURA) by 214.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,715 shares of the company's stock after buying an additional 103,411 shares during the period.
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KURA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.